凱撒旅遊(000796.SZ):股東海航旅遊再減持315萬股
格隆匯10月29日丨凱撒旅遊(000796.SZ)公佈,公司近日接股東海航旅遊通知,海航旅遊根據其自身安排,結合前期披露的減持計劃,於10月24、25日將質押於宏信證券的公司股份以大宗交易方式進行減持,減持數量為315萬股,佔公司總股本的0.39%,減持均價為6.60元/股。此次減持後,海航旅遊持有公司股份2.1204億股,佔公司總股本的26.41%。
截至2019年10月28日,海航旅遊及其一致行動人按照前次減持計劃通過集中競價合計減持公司股份103萬股,佔總股本的0.13%;通過大宗交易合計減持公司股份1457萬股,佔總股本的1.81%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.